A 17-year-old white male with Crohn's disease who was receiving maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented with a new-onset psoriasiform skin rash.

Infliximab injectable solution is a prescription medication that’s used to treat arthritis, ulcerative colitis, and other inflammatory diseases. It’s available only as the brand-name drugs ...

From 2020 to 2021, a total of 8,388 infliximab infusions were administered to the 863 patients in the study. Of these, 39 patients experienced 49 AEs.

To compare cyclophosphamide vs. infliximab (Remicade, Janssen) as first-line therapies in severe Behçet’s syndrome, Saadoun and colleagues conducted a phase 2, open-label, randomized controlled ...

Reason for posting : Remicade (infliximab), a tumour necrosis factor-α (TNF-α) antagonist, is used in the treatment of rheumatoid arthritis and Crohn's disease. However, the US Food and Drug ...

Here we describe a patient receiving infliximab who had reactivation of cerebral toxoplasmosis. The patient was a 36-year-old woman in whom rheumatoid arthritis was diagnosed in 2000.

The readministration of infliximab resulted in prompt improvement in the disease activity of the rheumatoid arthritis (), meeting the criteria of the American College of Rheumatology for remission ...

A 17-year-old white male with a 9-year history of ileocolonic Crohn's disease developed a skin rash while receiving infliximab, a chimeric IgG1κ monoclonal antibody against tumor necrosis factor ...